Clinical Trial Update: Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study of the investigational inhaled agent GSK233705B in chronic obstructive pulmonary disease has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK233705B

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2017-09-07